SGLT2 Inhibitors-A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling.
作者信息
Yagi Takashi, Kolluru Gopi K
机构信息
Department of Pathology LSU Health Shreveport Shreveport LA.
出版信息
J Am Heart Assoc. 2022 Aug 2;11(15):e026774. doi: 10.1161/JAHA.122.026774. Epub 2022 Jul 29.
Abstract
摘要
相似文献
1
SGLT2 Inhibitors-A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling.钠-葡萄糖协同转运蛋白2抑制剂——一项医学新发现：卡格列净引发高血压和血管重塑的分子信号传导
J Am Heart Assoc. 2022 Aug 2;11(15):e026774. doi: 10.1161/JAHA.122.026774. Epub 2022 Jul 29.
2
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.钠-葡萄糖协同转运蛋白2抑制剂对血压的影响。
Vasc Health Risk Manag. 2016 Oct 27;12:393-405. doi: 10.2147/VHRM.S111991. eCollection 2016.
3
Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对血压的影响使其成为糖尿病合并高血压患者的一个有吸引力的选择。
J Am Soc Hypertens. 2016 Mar;10(3):186-7. doi: 10.1016/j.jash.2016.01.001.
4
Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition.糖尿病中的夜间高血压：钠/葡萄糖协同转运蛋白2（SGLT2）抑制的潜在靶点。
J Clin Hypertens (Greenwich). 2018 Mar;20(3):424-428. doi: 10.1111/jch.13229. Epub 2018 Feb 19.
5
Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [ F]Canagliflozin in Patients with Type 2 Diabetes.评估卡格列净在 2 型糖尿病患者中的分布和钠-葡萄糖协同转运蛋白 2 占有率的可行性研究：使用 [ F]卡格列净。
Clin Pharmacol Ther. 2023 Jun;113(6):1295-1303. doi: 10.1002/cpt.2886. Epub 2023 Mar 26.
6
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.钠-葡萄糖共转运蛋白 2 抑制剂与其他降糖药物治疗 2 型糖尿病患者的心血管死亡率和发病率（CVD-REAL Nordic）：一项多国观察性分析。
Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3.
7
Canagliflozin and cardiovascular outcomes in Type 2 diabetes.卡格列净与 2 型糖尿病的心血管结局。
Future Cardiol. 2021 Jan;17(1):39-48. doi: 10.2217/fca-2020-0029. Epub 2020 Aug 4.
8
Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication.用于治疗大量白蛋白尿的钠-葡萄糖协同转运蛋白2抑制剂：一种新适应症。
J Diabetes. 2020 Jan;12(1):8-9. doi: 10.1111/1753-0407.13005. Epub 2019 Nov 13.
9
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的降压及肾脏作用机制
Hypertension. 2020 Apr;75(4):894-901. doi: 10.1161/HYPERTENSIONAHA.119.11684. Epub 2020 Mar 2.
10
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.抗糖尿病药物对2型糖尿病大血管并发症发生率和死亡率的影响：钠-葡萄糖协同转运蛋白2抑制剂的新视角
Ann Med. 2017 Feb;49(1):51-62. doi: 10.1080/07853890.2016.1226514. Epub 2016 Sep 22.
本文引用的文献
1
Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt-Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling.钠-葡萄糖共转运蛋白 2 抑制剂坎格列净通过调节瞬时受体电位通道 3 介导的血管钙处理拮抗盐敏感性高血压。
J Am Heart Assoc. 2022 Aug 2;11(15):e025328. doi: 10.1161/JAHA.121.025328. Epub 2022 Jul 29.
2
The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis.钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭中的作用：一项系统评价和荟萃分析。
Cardiol Res Pract. 2021 Aug 19;2021:9927533. doi: 10.1155/2021/9927533. eCollection 2021.
3
SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂可降低心力衰竭患者的心血管死亡和心力衰竭住院率：一项系统评价和荟萃分析。
EClinicalMedicine. 2021 Jun 5;36:100933. doi: 10.1016/j.eclinm.2021.100933. eCollection 2021 Jun.
4
Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.钠-葡萄糖协同转运蛋白2抑制剂对射血分数降低的心力衰竭患者的心肾益处：作用机制与临床证据
Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):311-321. doi: 10.1093/ehjcvp/pvab056.
5
Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options.慢性肾脏病中的心血管疾病：病理生理学见解与治疗选择。
Circulation. 2021 Mar 16;143(11):1157-1172. doi: 10.1161/CIRCULATIONAHA.120.050686. Epub 2021 Mar 15.
6
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
7
Sodium Intake and Chronic Kidney Disease.钠摄入与慢性肾脏病。
Int J Mol Sci. 2020 Jul 3;21(13):4744. doi: 10.3390/ijms21134744.
8
Role of Transient Receptor Potential Canonical Channels in Heart Physiology and Pathophysiology.瞬时受体电位香草酸通道在心脏生理和病理生理中的作用。
Front Cardiovasc Med. 2020 Feb 25;7:24. doi: 10.3389/fcvm.2020.00024. eCollection 2020.
9
Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease.钠-葡萄糖协同转运蛋白 2 抑制剂对慢性肾脏病非糖尿病大鼠模型血压盐敏感性和交感神经活性的影响。
Hypertens Res. 2020 Jun;43(6):492-499. doi: 10.1038/s41440-020-0410-8. Epub 2020 Feb 14.
10
High-salt intake increases TRPC3 expression and enhances TRPC3-mediated calcium influx and systolic blood pressure in hypertensive patients.高盐摄入增加 TRPC3 的表达，并增强高血压患者的 TRPC3 介导的钙离子内流和收缩压。
Hypertens Res. 2020 Jul;43(7):679-687. doi: 10.1038/s41440-020-0409-1. Epub 2020 Feb 10.
Zotero 插件